BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will invest $97 million to expand its clinical research operations in Richmond, Virginia.

GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating accessibility to messenger RNA products in emerging markets globally.

Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined data from the Ontario Cancer Registry from September 25, 2016 through September 26, 2020, to determine the impact of the COVID-19 pandemic on the number of new cancer cases detected.

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s two ongoing Phase 2 clinical trials of its vaccine candidate, GEO-CM04S1, against SARS-CoV-2.

Albany NY, United States: The global phototherapy equipment market is highly competitive in nature and is expected to witness an increased level of competition throughout the forecast period, states a new research report by Transparency Market Research.

Albany NY, United States: A new research report on the global non-opioid pain patch market expects that the market will achieve a stellar growth in the next few years of the mentioned forecast period of 2016 to 2024.

Albany NY, United States: Transparency Market Research has published a new report titled, ‘Clinical Laboratory Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Albany NY, United States: The increasing frequency in the number of cancer cases worldwide has propelled the growth of the global cancer biomarkers market.

DUBAI, United Arab Emirates, Academic institutes and hospitals use 3D printing technology to develop various models for training purposes.

Asieris Pharmaceuticals announced that the Hainan Provincial Medical Products Administration, in accordance with advice from the National Medical Products Administration Center for Drug Evaluation, has approved the inclusion of Asieris’ drug Hexvix®, a drug for the diagnosis of bladder cancer, in the clinical real-world evidence pilot study.